# Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients

> **NCT00782574** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 57 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AZD2281
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00782574
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-12
- **Primary completion:** 2012-02-01
- **Final completion:** 2023-12-07
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782574, "Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00782574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*